{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:22:12Z","timestamp":1740122532274,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although low-dose direct oral anticoagulants (DOACs) are recommended for patients at high risk of bleeding complications, it remains unclear whether the dose reduction in real-world setting is also appropriate in patients after large-vessel occlusion (LVO) stroke. This study hypothesized that patients with atrial fibrillation (AF) and LVO receiving low-dose DOACs have an increased risk of ischemic and hemorrhagic events. The study aimed to assess 1 year morbidity and mortality in patients treated with standard-dose and low-dose apixaban after LVO stroke. A post hoc analysis was performed using the acute LVO registry data, which enrolled patients with AF and LVO who received apixaban within 14\u00a0days of stroke onset. The incidences of ischemic events (ischemic stroke, acute coronary syndrome, acute myocardial infarction, and systemic embolism), major bleeding events, and death from any cause were compared between patients receiving standard- and low-dose apixaban. Of 643 patients diagnosed with LVO, 307 (47.7%) received low-dose apixaban. After adjustment for clinically relevant variables, no significant differences were observed in the incidence of ischemic events (adjusted hazard ratio [aHR]: 2.12, 95% confidence interval [CI] 0.75\u20136.02), major bleeding events (aHR: 1.17, 95% CI 0.50\u20132.73), and death from any cause (aHR: 1.95, 95% CI 0.78\u20134.89) between patients receiving standard- and low-dose apixaban. No significant differences were observed in the incidence of ischemic events, major bleeding events, or death from any cause between patients with AF and LVO receiving standard- and low-dose apixaban.<\/jats:p>","DOI":"10.1007\/s11239-024-02954-7","type":"journal-article","created":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T16:01:25Z","timestamp":1711900885000},"page":"622-629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["One-year morbidity and mortality in patients treated with standard-dose and low-dose apixaban after acute large vessel occlusion stroke"],"prefix":"10.1007","volume":"57","author":[{"given":"Yasutaka","family":"Murakami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-3466","authenticated-orcid":false,"given":"Kenichi","family":"Todo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Gon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,31]]},"reference":[{"key":"2954_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992. https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"2954_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jjcc.2019.07.007","volume":"75","author":"H Inoue","year":"2020","unstructured":"Inoue H, Umeyama M, Yamada T, Hashimoto H, Komoto A, Yasaka M (2020) Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a sub-analysis of the STANDARD study. J Cardiol 75:208\u2013215. https:\/\/doi.org\/10.1016\/j.jjcc.2019.07.007","journal-title":"J Cardiol"},{"key":"2954_CR3","doi-asserted-by":"publisher","first-page":"e008150","DOI":"10.1161\/JAHA.117.008150","volume":"7","author":"YH Chan","year":"2018","unstructured":"Chan YH, See LC, Tu HT, Yeh YH, Chang SH, Wu LS, Lee HF, Wang CL, Kuo CF, Kuo CT (2018) Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc 7:e008150. https:\/\/doi.org\/10.1161\/JAHA.117.008150","journal-title":"J Am Heart Assoc"},{"key":"2954_CR4","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/cpt.1952","volume":"108","author":"M Salameh","year":"2020","unstructured":"Salameh M, Gronich N, Stein N, Kotler A, Rennert G, Auriel E, Saliba W (2020) Stroke and bleeding risks in patients with atrial fibrillation treated with reduced apixaban dose: a real-life study. Clin Pharmacol Ther 108:1265\u20131273. https:\/\/doi.org\/10.1002\/cpt.1952","journal-title":"Clin Pharmacol Ther"},{"key":"2954_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/clc.23294","volume":"43","author":"K Okumura","year":"2020","unstructured":"Okumura K, Yamashita T, Suzuki S, Akao M, Investigators J-ELDAF (2020) A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry). Clin Cardiol 43:251\u2013259. https:\/\/doi.org\/10.1002\/clc.23294","journal-title":"Clin Cardiol"},{"key":"2954_CR6","doi-asserted-by":"publisher","first-page":"e059311","DOI":"10.1136\/bmjopen-2021-059311","volume":"12","author":"A Gonz\u00e1lez-P\u00e9rez","year":"2022","unstructured":"Gonz\u00e1lez-P\u00e9rez A, Roberts L, Vora P, Saez ME, Brobert G, Fatoba S, Garc\u00eda Rodr\u00edguez LA (2022) Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case-control analyses from UK primary care. BMJ Open 12:e059311. https:\/\/doi.org\/10.1136\/bmjopen-2021-059311","journal-title":"BMJ Open"},{"key":"2954_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/STROKEAHA.118.023093","volume":"50","author":"MS Cho","year":"2019","unstructured":"Cho MS, Yun JE, Park JJ, Kim YJ, Lee J, Kim H, Park DW, Nam GB (2019) Outcomes after use of standard- and low-dose non-vitamin k oral anticoagulants in asian patients with atrial fibrillation. Stroke 50:110\u2013118. https:\/\/doi.org\/10.1161\/STROKEAHA.118.023093","journal-title":"Stroke"},{"key":"2954_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/joim.12683","volume":"283","author":"L Staerk","year":"2018","unstructured":"Staerk L, Gerds TA, Lip GYH, Ozenne B, Bonde AN, Lamberts M, Fosb\u00f8l EL, Torp-Pedersen C, Gislason GH, Olesen JB (2018) Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med 283:45\u201355. https:\/\/doi.org\/10.1111\/joim.12683","journal-title":"J Intern Med"},{"key":"2954_CR9","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1161\/STROKEAHA.115.008891","volume":"46","author":"M Paciaroni","year":"2015","unstructured":"Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, Rueckert C, Pezzini A, Poli L, Padovani A et al (2015) Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF Study. Stroke 46:2175\u20132182. https:\/\/doi.org\/10.1161\/STROKEAHA.115.008891","journal-title":"Stroke"},{"key":"2954_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12975-020-00839-4","volume":"12","author":"S Yoshimura","year":"2021","unstructured":"Yoshimura S, Uchida K, Sakai N, Imamura H, Yamagami H, Tanaka K, Ezura M, Nonaka T, Matsumoto Y, Shibata M et al (2021) Safety of early administration of apixaban on clinical outcomes in patients with acute large vessel occlusion. Transl Stroke Res 12:266\u2013274. https:\/\/doi.org\/10.1007\/s12975-020-00839-4","journal-title":"Transl Stroke Res"},{"key":"2954_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263\u2013272. https:\/\/doi.org\/10.1378\/chest.09-1584","journal-title":"Chest"},{"key":"2954_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.str.19.5.604","volume":"19","author":"JC van Swieten","year":"1988","unstructured":"van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604\u2013607. https:\/\/doi.org\/10.1161\/01.str.19.5.604","journal-title":"Stroke"},{"key":"2954_CR13","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/01.str.25.11.2220","volume":"25","author":"P Lyden","year":"1994","unstructured":"Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J (1994) Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group Stroke 25:2220\u20132226. https:\/\/doi.org\/10.1161\/01.str.25.11.2220","journal-title":"NINDS TPA Stroke Study Group Stroke"},{"key":"2954_CR14","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1161\/STROKEAHA.113.001972","volume":"44","author":"OO Zaidat","year":"2013","unstructured":"Zaidat OO, Yoo AJ, Khatri P, Tomsick TA, von Kummer R, Saver JL, Marks MP, Prabhakaran S, Kallmes DF, Fitzsimmons B-FM et al (2013) Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 44:2650\u20132663. https:\/\/doi.org\/10.1161\/STROKEAHA.113.001972","journal-title":"Stroke"},{"key":"2954_CR15","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/STROKEAHA.115.010049","volume":"46","author":"R von Kummer","year":"2015","unstructured":"von Kummer R, Broderick JP, Campbell BCV, Demchuk A, Goyal M, Hill MD, Treurniet KM, Majoie CBLM, Marquering HA, Mazya MV et al (2015) The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke 46:2981\u20132986. https:\/\/doi.org\/10.1161\/STROKEAHA.115.010049","journal-title":"Stroke"},{"key":"2954_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"key":"2954_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"2954_CR18","doi-asserted-by":"publisher","first-page":"105034","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105034","volume":"29","author":"M Yasaka","year":"2020","unstructured":"Yasaka M, Umeyama M, Kataoka H, Inoue H (2020) Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study. J Stroke Cerebrovasc Dis 29:105034. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2020.105034","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2954_CR19","doi-asserted-by":"publisher","first-page":"e031341","DOI":"10.1136\/bmjopen-2019-031341","volume":"9","author":"LA Garc\u00eda Rodr\u00edguez","year":"2019","unstructured":"Garc\u00eda Rodr\u00edguez LA, Mart\u00edn-P\u00e9rez M, Vora P, Roberts L, Balabanova Y, Brobert G, Fatoba S, Suzart-Woischnik K, Schaefer B, Ruigomez A (2019) Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. BMJ Open 9:e031341. https:\/\/doi.org\/10.1136\/bmjopen-2019-031341","journal-title":"BMJ Open"},{"key":"2954_CR20","doi-asserted-by":"publisher","first-page":"101652","DOI":"10.1016\/j.arr.2022.101652","volume":"79","author":"M Proietti","year":"2022","unstructured":"Proietti M, Romiti GF, Raparelli V, Diemberger I, Boriani G, Dalla Vecchia LA, Bellelli G, Marzetti E, Lip GY, Cesari M (2022) Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1,187,000 patients. Ageing Res Rev 79:101652. https:\/\/doi.org\/10.1016\/j.arr.2022.101652","journal-title":"Ageing Res Rev"},{"key":"2954_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/ageing\/afy180","volume":"48","author":"C Wilkinson","year":"2019","unstructured":"Wilkinson C, Todd O, Clegg A, Gale CP, Hall M (2019) Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis. Age Ageing 48:196\u2013203. https:\/\/doi.org\/10.1093\/ageing\/afy180","journal-title":"Age Ageing"},{"key":"2954_CR22","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.3390\/jcm9092713","volume":"9","author":"R Krittayaphong","year":"2020","unstructured":"Krittayaphong R, Chichareon P, Komoltri C, Kornbongkotmas S, Yindeengam A, Lip GYH (2020) Low body weight increases the risk of ischemic stroke and major bleeding in atrial fibrillation: the COOL-AF registry. J Clin Med Res 9:2713. https:\/\/doi.org\/10.3390\/jcm9092713","journal-title":"J Clin Med Res"},{"key":"2954_CR23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1253\/circj.CJ-14-1245","volume":"79","author":"Y Hamatani","year":"2015","unstructured":"Hamatani Y, Ogawa H, Uozumi R, Iguchi M, Yamashita Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K et al (2015) Low body weight is associated with the incidence of stroke in atrial fibrillation patients\u2014insight from the fushimi AF registry. Circ J 79:1009\u20131017. https:\/\/doi.org\/10.1253\/circj.CJ-14-1245","journal-title":"Circ J"},{"key":"2954_CR24","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1161\/STROKEAHA.121.036695","volume":"53","author":"S Kimura","year":"2022","unstructured":"Kimura S, Toyoda K, Yoshimura S, Minematsu K, Yasaka M, Paciaroni M, Werring DJ, Yamagami H, Nagao T, Yoshimura S et al (2022) Practical \u201c1-2-3-4-Day\u201d rule for starting direct oral anticoagulants after ischemic stroke with atrial fibrillation: combined hospital-based cohort study. Stroke 53:1540\u20131549. https:\/\/doi.org\/10.1161\/STROKEAHA.121.036695","journal-title":"Stroke"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02954-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02954-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02954-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:11:03Z","timestamp":1713442263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02954-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,31]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2954"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02954-7","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2024,3,31]]},"assertion":[{"value":"25 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Todo reports lecture fees from Pfizer, Bristol-Myers Squibb, Daiichi-Sankyo, Bayer. K. Uchida reports lecturer\u2019s fees from Daiichi Sankyo. H. Yamagami discloses research grants from Bristol-Myers Squibb; lecturer\u2019s fees from Bayer, Daiichi Sankyo, Bristol-Myers Squibb, Otuska Pharmaceutical, Stryker and Medtronic; and membership of the advisory boards for Daiichi Sankyo. N. Sakai reports lecturer\u2019s fees from Daiichi Sankyo. S. Yoshimura discloses research grants from Bristol-Myers Squibb and lecturer\u2019s fees from Boehringer Ingelheim, Daiichi Sankyo, Bayer, Pfizer, and Bristol-Myers Squibb. T. Morimoto reports lecturer\u2019s fees from Daiichi Sankyo and Pfizer, a manuscript fee from Pfizer, and membership of the advisory boards for Bristol-Myers Squibb. No other disclosures were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and all methods were carried out per the relevant guidelines and regulations for observational studies. The institutional review boards of all 38 participating centers approved the study protocol. This procedure was approved by the institutional review boards in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"A written informed consent was obtained from the prospectively registered patients and from the opt-out method from the retrospectively registered patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}